Berberine ameliorates intestinal mucosal barrier dysfunction in nonalcoholic fatty liver disease (NAFLD) rats

被引:10
|
作者
Wang, Yuzhen [1 ]
Cui, Suxian [2 ]
Zheng, Jimin [1 ]
Li, Yueqin [1 ]
Li, Pingping [1 ]
Hou, Hongtao [1 ]
机构
[1] Hebei Gen Hosp, Dept Gastroenterol, Shijiazhuang 050051, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Gastroenterol, Shijiazhuang 050017, Hebei, Peoples R China
关键词
Nonalcoholic fatty liver disease; Berberine; Intestinal mucosal barrier; ENDOTOXEMIA; DIET; NOD1;
D O I
10.1016/j.jksus.2020.03.019
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To study the protective role of berberine (BBR) against nonalcoholic fatty liver disease (NAFLD) on intestinal barrier via investigating its effect on intestinal permeability and intestinal innate immune system in a rat model. Method: Sprague-Dawley rats were randomly divided into three groups: control rats (group N), high-fat diet (HFD) model rats (group M) and BBR-treated rats (group B). Rats in group M and group B were fed with HFD for 12 weeks to induce NAFLD. Rats in group B were then received 4 weeks of BBR administration with continuous HFD feeding. Samples were collected at 16th week. Results: HFD feeding increased the body weight of rats and caused liver steatosis as indicated by hematoxylin & eosin (H&E) staining. Analysis of serum parameters showed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), endotoxin, interleukin-1 beta (IL-1 beta), interleukin-18 (IL-18), and tumor necrosis factor-alpha (TNF-alpha) were significantly higher in group M as compared group N. These results confirmed the successful establishment of NAFLD in rats. With 4 weeks of BBR administration, body weight of group B decreased significantly as compared with group M. Serum levels of ALT, AST, TC, TG, endotoxin, IL-1 beta, IL-18 and TNF-alpha reduced significantly and hepatocyte steatosis ameliorated. RT-PCR and Western blot analysis showed that BBR reduced the elevated mRNA and protein expressions of innate immune response elements NOD1, NOD2 and NLRP3 that were caused by HFD. BBR also antagonized the effect of NAFLD on Caspase-1 and Claudin-4 protein expressions. Conclusions: BBR alleviates endotoxemia, reduces serum lipids, increases liver function, reduces systemic inflammation and diminishes liver inflammation and steatosis in NAFLD rats. The protective effect of BBR against NALFD is achieved through ameliorating intestinal mucosal barrier dysfunction partly by improving permeability of intestinal mucosa and modulating intestinal innate immune components. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:2534 / 2539
页数:6
相关论文
共 50 条
  • [31] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
  • [32] Antioxidant Activates AMPK and Ameliorates Nonalcoholic Fatty Liver Disease in OLETF Rats
    Park, Yongsoo
    Kim, Hyunok
    DIABETES, 2014, 63 : A469 - A469
  • [33] Testosterone Replacement Ameliorates Nonalcoholic Fatty Liver Disease in Castrated Male Rats
    Nikolaenko, L.
    Jia, Y.
    Wang, C.
    Diaz-Arjonilla, M.
    Yee, J. K.
    French, S. W.
    Liu, P. Y.
    Laurel, S.
    Chong, C.
    Lee, K.
    Lue, Y.
    Lee, W. N. P.
    Swerdloff, R. S.
    ENDOCRINOLOGY, 2014, 155 (02) : 417 - 428
  • [34] Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles
    Xinlu Yuan
    Jie Wang
    Xiaoyan Tang
    Yixue Li
    Pu Xia
    Xin Gao
    Journal of Translational Medicine, 13
  • [35] Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles
    Yuan, Xinlu
    Wang, Jie
    Tang, Xiaoyan
    Li, Yixue
    Xia, Pu
    Gao, Xin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [36] CHARACTERISTICS OF THE FATTY ACID COMPOSITION IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Yamada, K.
    Mizukoshi, E.
    Takeshita, Y.
    Arai, K.
    Yamashita, T.
    Sakai, A.
    Kaneko, S.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S505 - S506
  • [37] Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice
    Qian, Minyi
    Lyu, Qianqian
    Liu, Yujie
    Hu, Haiyang
    Wang, Shilei
    Pan, Chuyue
    Duan, Xubin
    Gao, Yingsheng
    Qi, Lian-wen
    Liu, Weizhi
    Wang, Lirui
    MARINE DRUGS, 2019, 17 (07)
  • [38] The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease
    Zhu, Xiaopeng
    Bian, Hua
    Gao, Xin
    MOLECULES, 2016, 21 (10)
  • [39] The clinical and pathological spectrum of nonalcoholic fatty liver liver disease (NAFLD)
    Copaci, I
    Voiculescu, M
    Micu, L
    Hortopan, M
    Cojocaru, L
    JOURNAL OF HEPATOLOGY, 2002, 36 : 255 - 255
  • [40] VASCULAR FUNCTION CHANGES IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)/ NONALCOHOLIC STEATOHEPATITIS
    Jafari, Kaveh
    Paquet, Veronique
    Addour, Saliha
    Fortie, Catherine
    Trepan, Gabrielle
    Ferlan, Stephanie
    Agharazii, Mohsen
    Carre, Anne-Marie
    JOURNAL OF HYPERTENSION, 2024, 42